Resource impact template
NICE has produced a resource impact template that incorporates the following technology appraisal guidance for wet age-related macular degeneration:
- Bevacizumab gamma for treating wet age-related macular degeneration (2024) NICE technology appraisal guidance 1022
- Faricimab for treating wet age-related macular degeneration (2022) NICE technology appraisal guidance 800
- Brolucizumab for treating wet age-related macular degeneration (2021) NICE technology appraisal guidance 672
- Aflibercept solution for injection for treating wet age‑related macular degeneration (2013) NICE technology appraisal guidance 294
- Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (2008) NICE technology appraisal guidance 155
This page was last updated: